Plasma-based therapeutic - Alkahest/Grifols

Drug Profile

Plasma-based therapeutic - Alkahest/Grifols

Alternative Names: Plasma-based therapeutic

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alkahest; Stanford University
  • Developer Alkahest; Griffith University
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Alzheimer's disease

Most Recent Events

  • 01 Nov 2017 Efficacy and adverse events data from a clinical trial in Alzheimer's disease released by Alkahest
  • 01 Nov 2017 Alkahest plans clinical studies for Alzheimer's disease
  • 04 Mar 2015 Preclinical trials in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top